title: Results of Therapy for Wilms Tumor and Other Malignant Kidney Tumors: A Report From the Chilean Pediatric National Cancer Program (PINDA).
abstract: The aim of this study was to analyze the survival of children with Wilms tumor and other malignant renal tumors treated with the TWPINDA-99 protocol.
  
  
  
  Between January 1999 and December 2013, 226 patients were registered on this trial, based on National Wilms Tumor Study-5. Patient characteristics and survival were evaluated.
  
  
  
  Two hundred seven patients were diagnosed with Wilms tumor, which represented 91.6% of renal tumors. The male to female ratio was 0.7:1. The median age at diagnosis was 3.3 years. Stage III was the most frequent (39.2%). Metastatic disease was present in 16.7% of the cases. Synchronous bilateral disease was observed in 9.3% of the cases. Favorable histology was diagnosed in 93.6% and anaplastic histology in 6.4% of the patients. Median follow-up was 7.5 years. Ten-year event-free survival and overall survival (OS) for assessable patients with Wilms tumor (n=192) were 82.0% and 89.9%, respectively. OS for patients with stage I was 100% (n=36), stage II: 97.1% (n=35), stage III: 88.6% (n=71), stage IV: 77.9% (n=32), and stage V: 80.8% (n=18). OS for favorable histology (n=180) and anaplastic histology tumors (n=12) were 91.0% and 72.9%, respectively. Other malignant renal tumors had a poorer survival.
  
  
  
  Prognosis for patients with Wilms tumor treated on TWPINDA-99 seems to be better than previous national trials and is similar to developed countries.
authors.affiliation: *Department of Hematology-Oncology, Hospital Roberto del Río †Department of Hematology-Oncology, Hospital Sótero del Río ‡Faculty of Medicine, University of Chile §Department of Hematology-Oncology, Hospital Luis Calvo Mackenna ∥Department of Hematology-Oncology, Hospital Exequiel González Cortés, Santiago ¶Department of Hematology-Oncology, Hospital Regional de Valdivia, Valdivia #Department of Hematology-Oncology, Hospital Grant Benavente, Concepción **Department of Hematology-Oncology, Hospital Regional de Temuco, Temuco ††Department of Hematology-Oncology, Hospital San Borja Arriarán, Santiago ‡‡Department of Hematology-Oncology, Hospital San Juan de Dios, Santiago §§Department of Hematology-Oncology, Hospital Gustavo Fricke, Viña del Mar ∥∥Department of Hematology-Oncology, Hospital Van Buren, Valparaíso ¶¶Department of Radiation Oncology, Instituto Nacional del Cáncer, Santiago, Chile.
authors.forename: Pilar
authors.initials: P
authors.lastname: Joannon
authors.forename: Ana
authors.initials: A
authors.lastname: Becker
authors.forename: Paola
authors.initials: P
authors.lastname: Kabalan
authors.forename: Emma
authors.initials: E
authors.lastname: Concha
authors.forename: Victoria
authors.initials: V
authors.lastname: Beresi
authors.forename: Carmen
authors.initials: C
authors.lastname: Salgado
authors.forename: Pilar
authors.initials: P
authors.lastname: Martínez
authors.forename: Paola
authors.initials: P
authors.lastname: Olate
authors.forename: Mónica
authors.initials: M
authors.lastname: Arriagada
authors.forename: Felipe
authors.initials: F
authors.lastname: Espinoza
authors.forename: Mónica
authors.initials: M
authors.lastname: Varas
authors.forename: Pablo
authors.initials: P
authors.lastname: Benavides
authors.forename: Miguel
authors.initials: M
authors.lastname: Valero
authors.forename: Mauricio
authors.initials: M
authors.lastname: Reyes
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002677:Chile; D019049:Developed Countries; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D009313:National Health Programs / Q000592:standards; D009367:Neoplasm Staging; D010372:Pediatrics; D015996:Survival Rate; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000401:mortality / Q000628:therapy*